Druck Icon

Eckert & Ziegler Receives Approval for Gallium-68 Generator for Canada

Berlin, 25 August 2020. Eckert & Ziegler Radiopharma GmbH has received approval for its pharmaceutical 68Ge/68Ga generator GalliaPharm(R) from the Canadian regulatory authority Health Canada.

"We are pleased to now be able to offer GalliaPharm(R) in Canada. Meanwhile, the generators from Eckert & Ziegler are available in more and more countries. If gallium-based diagnostics become widely accepted in the coming years, we are well prepared as supplier", explains Dr. Lutz Helmke, member of the Executive Board of Eckert & Ziegler AG and responsible for the Medical segment. "Since there are currently many clinical studies with so-called theranostics worldwide, we expect an increasing demand for both the diagnostic radioisotope gallium-68 and the therapeutic radioisotope lutetium-177 in the next few years".

GalliaPharm(R) is already successfully used for the diagnosis of neuroendocrine tumors and also for prostate cancer (Ga-68-PSMA).

Gallium generators offer a low-cost alternative to radioactive labeling of biomolecules with gallium-68 in PET, an imaging examination method used to detect the presence or absence of diseased tissue. The procedure is used primarily in the diagnosis of cancer, heart attacks or neurological diseases. Up to now, the radioisotopes fluorine-18 or carbon-11 have mostly been used to label biomolecules. This requires millions of dollars of investment in large-scale equipment (cyclotrons). The 68Ge/68Ga generator, on the other hand, is about the size of a thermos flask and can be obtained much more cheaply, which reduces costs and increases flexibility in nuclear medical clinics and practices.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

For further information or questions, please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.de